Polymyositis is a disease that causes inflammation and weakness in muscles. The condition is thought to be an autoimmune disease. Physical therapy is one of the important components of treatment.
Polymyositis is an inflammatory muscle disease that causes muscle weakness. Myositis means inflammation of muscle. Usually, polymyositis affects the muscles that are closest to the trunk of the body. Eventually, people with polymyositis have trouble when rising from a sitting position, climbing stairs, lifting objects, or reaching overhead. In some cases, muscles that are not close to the trunk of the body become affected as the disease progresses.
Polymyositis develops gradually over time, and it rarely affects persons younger than age 18. It is more common in women (by about 2 to 1).
If the condition is accompanied by an inflammatory process that strikes the skin as well, it is called dermatomyositis.
Polymyositis can be present in combination with other illnesses. Both polymyositis and dermatomyositis can sometimes be associated with cancers, including lymphoma, breast, lung, ovarian, and colon cancer.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The cause of polymyositis is not known, but there are indications that heredity plays a role in the disease.
Current research suggests that the condition may occur when immune system cells infiltrate and attack muscle tissue (an autoimmune process).
Research into the workings of the immune system and what causes it to malfunction may result in more knowledge about the causes of polymyositis.
The following are some symptoms of polymyositis. These symptoms may come and go:
The diagnosis of the disease usually begins with a physician’s exam and blood testing. People who have polymyositis often have unusually high levels of muscle enzymes. The enzymes are released into the blood by muscle that is being damaged by inflammation. Routine blood and urine tests can check for internal organ abnormalities. Chest X-rays, mammograms, PAP smears, and other screening tests might be considered to look for signs of cancers that may arise with polymyositis. Additional testing can rule out other conditions resembling polymyositis.
Electromyography (EMG) and nerve conduction velocity studies are electrical tests of muscle and nerves that can show abnormal findings typical of polymyositis. These tests also can rule out other nerve-muscle diseases. Imaging of the muscles can show areas of muscle inflammation and can be used to find muscle biopsy sites.
Muscle biopsy is a surgical procedure in which muscle tissue is removed and examined. A muscle biopsy is used to confirm the presence of muscle inflammation typical only of polymyositis.
Polymyositis is treated with high doses of corticosteroids as a first course of treatment. Corticosteroids are given because they can effectively decrease the inflammation in the muscles. Corticosteroids do not always adequately improve polymyositis. In these patients immunosuppressive medications are considered. These medicines include:
In severe cases of polymyositis, the intravenous infusion of immunoglobulins (IVIG) has been an effective treatment. Physical therapy also is important in the treatment of polymyositis.
With early medical treatment of the disease and disease flares, patients with polymyositis can do well. The disease frequently becomes inactive, enabling the patient to focus on muscle rehabilitation.
Muscular Dystrophy Association - USA
161 N. Clark, Suite 3550
Chicago, IL 60601
Toll free: 800.572.1717
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Information Clearinghouse
National Institutes of Health
Bethesda, MD 20892-3675
Toll free: 877.226.4267 (877.22NIAMS)
1940 Duke St.
Alexandria, VA 22314
Toll free: 800.821.7356
National Organization for Rare Disorders (NORD)
National Headquarters, CT Office
55 Kenosia Avenue
Danbury, CT 06810
Last reviewed by a Cleveland Clinic medical professional on 04/02/2019.
Learn more about our editorial process.